Pioneers in EHR Marketing, Ushering in AI-Based Omnichannel Transformation.

Steve Silvestro brings more than 20 years’ experience in direct operations, sales, and partner network growth, to lead revenue activities and strengthen the go-to-market. 

Steve is responsible for driving OptimizeRx's platform revenue growth including enterprise-level direct-to-patient and direct-to-provider product adoption to improve patient outcomes.

During his tenure at Decision Resources Group, he was an instrumental leader in the growth of the company from $30 million to $180 million in revenue. His customer-first philosophy is greatly aligned to our values at OptimizeRx.

Steve previously served as vice president and general manager at CCH Tagetik, a division of Wolters Kluwer. Prior pharma leadership experience includes executive positions with Prognos, Decision Resources Group and D.M.S. Silvestro has extensive channel expertise in biopharma commercialization, global market access, market research, analytics, enterprise SaaS solutions and strategy. 

Silvestro received a master’s degree in Business Management from Harvard University. He also holds undergraduate degrees from Brigham Young University in both Business and Italian. He is fluent in English, Italian, Spanish and conversational in French.

A seasoned leader with a passion for innovation in healthcare, Theresa brings over 25 years of experience driving commercial success. Her expertise spans healthcare data, analytics, technology, and consulting services.

In October 2023, she joined OptimizeRx as its Chief Commercial Officer following the Company’s acquisition of Healthy Offers, Inc. (“Medicx Health”), where she served as President. Previously, Theresa held Chief Commercial Officer positions at leading healthcare companies such as MediSpend and Prognos Health where she led product strategy, marketing, sales, and customer delivery. 

Her career includes notable roles at LexisNexis Healthcare, where she contributed to revenue growth and profitability. Additionally, she led the Life Sciences consulting group at Computer Sciences Corporation and held various positions at IQVIA and Pfizer.  

Theresa holds a Master of Business Administration in Healthcare Administration Management from Temple University. She completed her undergraduate studies at Ursinus College, earning a Bachelor of Science degree.

Ed has over 30 years of diverse experience at organizations going through transformational changes, including international expansions, new product launches, financial/operational turnarounds, mergers & acquisitions, resource prioritization, strategy creation, and digital innovation. In his senior leadership roles, Ed has continually brought lasting positive culture changes and purpose to the organizations he serves.

Prior to joining OptimizeRx Ed served in a variety of leadership roles at Otsuka America Pharmaceuticals Inc. His tenure with Otsuka began as a CFO leading the finance team on a transformative journey to help steer the organization through Abilify loss of exclusivity (LOE). It culminated in an appointment as CFO/COO to lead a ~400 person, multi-functional team of professionals through product lifecycle management, new product launches, strategy development, alliance governance, M&A and COVID-19 response. Over his tenure, the US organization evolved to be one of the best performing businesses for Otsuka globally and built best-in-class capabilities across a number of key enterprise functions through significant process optimization and automation initiatives.

Ed’s career has taken him across the globe, including foreign expat assignments in the Netherlands and Russia. He has held positions of increasing responsibilities in finance and operations at Covance/LabCorp, Mylan, Organon/Schering-Plough, Sanofi-Aventis and Johnson & Johnson.

Outside of work, Ed serves as the Treasurer and Executive Committee member of the American Foundation of Suicide Prevention in NYC, and as a member of the Advisory Committee of the Arts Council of Princeton.

He received his Bachelor of Science in Finance from Towson University and his MBA from the University of Baltimore. He is also a Certified Public Accountant (inactive) in the State of New Jersey and a Certified Management Accountant. He is married with two adult children, and fluent in Russian.

Marion is a corporate lawyer with over 25 years of large firm and in-house experiences in a broad range of industries including life sciences, biotech, high tech, business consulting, professional services, banking and finance companies. She is a critical thinker with strong global management, leadership, analytical, communication and problem-solving skills with emphasis on providing practical and proactive solutions to complex legal and business issues in both the domestic and international arenas. 

Marion oversees the Compliance/Corporate Governance, Legal/Contracts and Human Resources teams. Her areas of expertise include corporate, mergers and acquisitions and securities; complex transactions and global commercial contracts; privacy and IT security compliance; technology and licensing; labor and employment; corporate policy development and training; and corporate governance and board relations. 

Prior to joining OptimizeRx, Marion worked in various leadership roles in both public and private companies. She began her legal career in private practice at the Boston law firm of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC, where she advised public and private companies on corporate matters.

Marion received her J.D. from Northeastern University, her M.Phil from the University of Cambridge, and her B.A. from Columbia University. Marion lives in Cambridge, Massachusetts, is married, has two adult children, and is fluent in Korean and proficient in Italian.

Dr. Doug Besch has nearly 20 years of experience in healthcare leadership. Throughout his career, Doug has demonstrated expertise in product strategy and innovation within the healthcare industry. 

Prior to his current role, he served as the Vice President of Market Access & Payer Solutions for Clarivate and Vice President of Payor Product & Innovation at Decision Resources Group. In these positions, he was instrumental in setting product vision and strategy, aligning cross-functional teams, and securing investments for strategic initiatives. 

Dr. Besch was a co-founder and the Chief Product Officer for Rx Savings Solution, a company that helps members and payers reduce prescription drug costs through a combination of clinical technology, transparency, member engagement, and concierge support. His professional journey began as a pharmacist for the Walgreens Boots Alliance.  

Dr. Besch holds a Doctor of Pharmacy (PharmD) degree and a Master of Business Administration from Creighton University, complemented by a Bachelor of Science from Simpson College.

Lynn is the President and CEO of the Muscular Dystrophy Association (MDA), the leader in the fight against muscular dystrophy and ALS through its funding of research, clinical care, support service, and education.

Lynn has a hands-on appreciation for patient care, and she has considerable executive experience and expertise in the fields of pharmacology, medical and clinical education, and digital marketing.

Prior to her arrival at MDA, Lynn was CEO of ghg | greyhealth group for nearly 23 years and is credited with creating, building and acquiring companies — specifically, nine acquisitions — to grow ghg’s global footprint. While at ghg, Vos led global expansion and diversification strategies and within two years grew the company from a small, domestic professional player into an award-winning global enterprise with fully integrated, multi-channel offerings.

She is a recognized thought leader in the industry with published white papers and articles outlining new, successful approaches to health care technology and communication.

Cathy Klema has over 30 years of experience in the healthcare industry. Prior to establishing Nettleton Advisors, she served as Managing Director in the Healthcare Investment Banking groups at SG Cowen Securities and Furman Selz LLC, where she advised clients on mergers and acquisitions, divestitures, public offerings, and other strategic transactions. Ms. Klema is currently Chair of the Board of Managers of Quorum Health, a leading health system with 12 hospitals across 10 states. She also serves on the Board of Trustees of Montefiore Health System, a prominent academic health system in New York City. Previously, she was a Director of Allergan plc, a global pharmaceutical company, and Pharmaceutical Product Development, Inc., a global contract research organization.

Mr. Lang brings to OptimizeRx more than 25 years of experience in healthcare data, analytic, and technology enabled business services.

Lang presently serves as an executive advisor to Water Street, a strategic private equity firm focused exclusively on building market-leading companies in healthcare. He is also a director of BioVie, a development-stage company pioneering an innovative therapeutic that targets complications due to liver cirrhosis.

Previously, Mr. Lang served as CEO of Decision Resources Group, DRG, a leading healthcare research and consulting company providing high-value healthcare industry analysis and insights, where he helped transform the company into an industry leader. Earlier, he was president of Strategic Decisions Group, a premier global strategy consultancy, and he expanded the life sciences practice and later sold it to IMS Health.

He is an active private investor and advisor with healthcare companies, including Boston Heart Diagnostics (acquired by Eurofins) and AlphalmpactRx (acquired by IMS Health).

James Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire, and earned an MBA with distinction from the Tuck School of Business where he was named an Edward Tuck Scholar.

He currently guest lectures at the Tuck School of Business in strategy and decision-making.

Patrick Spangler has over 32 years of experience in IPO’s, mergers and acquisitions, operations and financial management experience in the medical device and health care IT industries. As a transformational leader he has been responsible for driving high-performance emerging growth firms as well as large publicly traded companies and has also served in the private equity sector successfully improving operational results and exit strategies with a broad array of portfolio companies. He currently serves as Chief Financial Officer of On Target Laboratories which has developed fluorescent markers to target and illuminate cancer during surgery. Prior to On Target Laboratories, Pat served as Chief Financial Officer of MHC Software supplying document automation software to a variety of industries. Previous to MHC, Pat served as Chief Financial Officer of Vigilanz Corporation, Chief Financial Officer of Healthland Inc, SVP and CFO for Epocrates (EPOC), SVP and CFO of ev3 Inc. (EVVV), and ... Executive Vice President and Chief Financial Officer and Assistant Secretary for EMPI Inc (EMPI). Prior to joining EMPI Inc. Pat served for over eleven years in various senior finance leadership positions at Medtronic, Inc (MDT).  

Pat holds a Bachelor of Science in Accounting from the University of Minnesota, a Master of Business Taxation from the University of Minnesota and a Master of Business Administration from University of Chicago and also serves on the Board of Directors of Lifespace Communities Inc, OptimizeRx (OPRX) and previously served on the board of Urologix Inc (ULGX) a leader in less invasive in office BPH treatment.

Greg Wasson founded Wasson Enterprise, a family office that partners to build sustainable, high-growth businesses that do well by doing good. Wasson Enterprise brings a wealth of knowledge, including leadership, operations and governance experience to those WE supports. Additionally, Greg is a Co-Founder of CoolerScreens, Co-Founder and Director of Golden Fleece Beverages Inc., Co-Founder of Innventure, and Executive Chairman of Innovation Associates.

As the former President and CEO of Walgreens, Greg led this Fortune 35 company to record fiscal 2014 sales of $76.4 billion. He is credited with creating significant financial and shareholder value, initiating and completing game-changing mergers and acquisitions, leading complex organizational and structural change, assembling a diverse and high-performance senior leadership team, and establishing Walgreens’ position as an industry leader. Before retiring from Walgreens, Greg had transformed an iconic 114-year-old domestic company into the first global pharmacy-led, health, well-being, and beauty enterprise via the successful merger with European-based Alliance Boots to create Walgreens Boots Alliance.

Greg began his career as a pharmacy services intern in the Walgreens corporate offices—an opportunity that led to his being hired by Walgreens upon graduation. Greg then spent many years in store operations, leading and opening new markets around the country. Greg also had the opportunity to run Walgreens Health Services which gave him a keen insight to the health care services side of the Walgreens business. This role eventually led to Greg becoming the COO of Walgreens. Greg was with Walgreens for 35 years, retiring as the President and CEO of Walgreens Boots Alliance. He received his BS in pharmacy in 1981 from Purdue University and is a registered pharmacist.

Greg serves on the boards of Health Care Service Corporation (HCSC), Cooler Screens, Performance Health Systems, Innovation Associates, Innventure, OptimizeRx, The Economic Club of Chicago, Corporate Leadership Center, and AUSL.